Pretreatment Tumor Growth Rate and Radiological Response as Predictive Markers of Pathological Response and Survival in Patients with Resectable Lung Cancer Treated by Neoadjuvant Treatment.

ABSTRACT:

Introduction

Predictive biomarkers associated with pathological response, progression precluding surgery, and/or recurrence after surgery are needed for patients with resectable non-small cell lung carcinoma (NSCLC) treated by neoadjuvant treatment. We evaluated the clinical impact of the pretreatment tumor growth rate (TGR₀) and radiological response for patients with resectable NSCLC treated with neoadjuvant therapies.

Methods

Consecutive patients with resectable stage IB (≥4 cm) to IIIA NSCLC treated by neoadjuvant platinum-doublet chemotherapy with or without nivolumab at our tertiary center were retrospectively analyzed. TGR₀ and RECIST objective responses were determined. Multivariable analyses identified independent predictors of event-free survi

SUBMITTER: Ramtohul T 

PROVIDER: S-EPMC10453282 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature